IL182096A0 - Methods for preparing indazole compounds - Google Patents

Methods for preparing indazole compounds

Info

Publication number
IL182096A0
IL182096A0 IL182096A IL18209607A IL182096A0 IL 182096 A0 IL182096 A0 IL 182096A0 IL 182096 A IL182096 A IL 182096A IL 18209607 A IL18209607 A IL 18209607A IL 182096 A0 IL182096 A0 IL 182096A0
Authority
IL
Israel
Prior art keywords
methods
indazole compounds
preparing indazole
preparing
compounds
Prior art date
Application number
IL182096A
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL182096A0 publication Critical patent/IL182096A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL182096A 2004-11-02 2007-03-21 Methods for preparing indazole compounds IL182096A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62457504P 2004-11-02 2004-11-02
PCT/IB2005/003300 WO2006048745A1 (en) 2004-11-02 2005-10-21 Methods for preparing indazole compounds

Publications (1)

Publication Number Publication Date
IL182096A0 true IL182096A0 (en) 2007-07-24

Family

ID=35528034

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182096A IL182096A0 (en) 2004-11-02 2007-03-21 Methods for preparing indazole compounds

Country Status (15)

Country Link
EP (1) EP1809625A1 (en)
JP (1) JP2008518901A (en)
KR (1) KR20070058689A (en)
CN (1) CN101044138A (en)
AR (1) AR051753A1 (en)
AU (1) AU2005300311A1 (en)
BR (1) BRPI0517921A (en)
CA (1) CA2586176A1 (en)
IL (1) IL182096A0 (en)
MX (1) MX2007003603A (en)
NO (1) NO20072747L (en)
RU (1) RU2007114112A (en)
TW (1) TW200614990A (en)
WO (1) WO2006048745A1 (en)
ZA (1) ZA200702317B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (en) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド Compound drug
FI2134702T4 (en) 2007-04-05 2023-09-12 Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
US8354528B2 (en) * 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
TW201328725A (en) 2011-09-30 2013-07-16 Pfizer Pharmaceutical compositions of N-methyl-2-3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl-benzamide
MX2014005715A (en) 2011-11-11 2014-05-28 Pfizer N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl ]-benzamide for the treatment of chronic myelogenous leukemia.
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN103387565B (en) * 2013-07-29 2014-10-29 苏州明锐医药科技有限公司 Preparation method of Axitinib
CN103570696B (en) * 2013-11-06 2016-02-24 湖南欧亚生物有限公司 A kind of preparation method of Axitinib intermediate and preparing the application in Axitinib
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
ES2710211T3 (en) 2014-02-04 2019-04-23 Pfizer Combination of a PD-1 antagonist and a VEGFR inhibitor to treat cancer
ES2647262T3 (en) * 2014-03-31 2017-12-20 Senju Pharmaceutical Co. Ltd Alkynyl indazole derivative and use thereof
CN104072484B (en) * 2014-07-07 2016-07-06 渤海大学 Nitrogen-(4-(aromatic thiohydroxy)-1 hydrogen-indazole-3-base)-1-(heteroaromatic replacement) methylene imine compounds and pharmaceutically acceptable salt and its preparation method and application thereof
JP2017530950A (en) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド Combination of PD-1 antagonist and ALK inhibitor for treating cancer
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
RU2714233C2 (en) 2015-02-26 2020-02-13 Мерк Патент Гмбх Pd-1/pd-l1 inhibitors for treating cancer
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
KR20190062515A (en) 2016-10-06 2019-06-05 화이자 인코포레이티드 Usage of Abelipab for the Treatment of Cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US20220194921A1 (en) 2019-04-18 2022-06-23 Synthon B.V. Process for preparation of axitinib
CN112209861A (en) * 2019-07-11 2021-01-12 鲁南制药集团股份有限公司 Acixtinib intermediate compound and preparation method thereof
CN112442010B (en) * 2019-08-30 2023-10-03 润佳(苏州)医药科技有限公司 Prodrug compounds and application thereof in treating cancers
CN111440102B (en) * 2020-04-26 2022-02-15 大连凯飞化学股份有限公司 Preparation method of dithiodibenzoamide compound
WO2023166420A1 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
CN114591338B (en) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 Preparation method and application of Syk and VEGFR2 double-target inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (en) * 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
CN1747950A (en) * 2002-12-19 2006-03-15 美国辉瑞有限公司 2-(1h-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
EP1606283B1 (en) * 2003-03-03 2008-10-08 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005094823A1 (en) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Flt-3 INHIBITOR

Also Published As

Publication number Publication date
AU2005300311A1 (en) 2006-05-11
CA2586176A1 (en) 2006-05-11
NO20072747L (en) 2007-07-31
EP1809625A1 (en) 2007-07-25
JP2008518901A (en) 2008-06-05
KR20070058689A (en) 2007-06-08
MX2007003603A (en) 2007-05-21
BRPI0517921A (en) 2008-10-21
AR051753A1 (en) 2007-02-07
TW200614990A (en) 2006-05-16
RU2007114112A (en) 2008-12-10
ZA200702317B (en) 2008-09-25
WO2006048745A1 (en) 2006-05-11
CN101044138A (en) 2007-09-26

Similar Documents

Publication Publication Date Title
IL182096A0 (en) Methods for preparing indazole compounds
ZA200704350B (en) Methods for preparing indazole compounds
IL182693A0 (en) Methods of preparing indazole compounds
ZA200704202B (en) Method for preparing n-phenylpyrazole-1-carboxamides
ZA200702977B (en) Methods of preparing indazole compounds
IL188600A0 (en) Method for preparing esomeprazole
TW200619222A (en) Method for making organometallic compounds
ZA200704535B (en) Process for preparing rosuvastatin
EP2001480A4 (en) Indazole compounds
EP1813677A4 (en) Process for producing basic substance
EP1828170A4 (en) Process for preparing voriconazole
IL178071A0 (en) Process for preparing pyridazinone compounds
EP2091329A4 (en) Indazole compounds
IL178001A0 (en) Process for preparing 5-methyl-2-furfural
TWI372145B (en) Process for preparing alkylanilides
EP1751123A4 (en) Process for preparing irbesartan
IL178069A0 (en) Process for preparing n-aryl-piperazine derivatives
IL208214A0 (en) Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
PL1711302T3 (en) Method for connecting components
EP2147916A4 (en) Method for the preparation of synthesized taxanoids
IL189574A0 (en) Process for preparing 1-substituted-5-acylimidazole compounds
HU0400305D0 (en) Set for spine-fixture
HU0501174D0 (en) Apparatus for introducing organwind
EP1713796A4 (en) Process for preparing substituted benzopyran compounds
IL183804A0 (en) Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes